Loading...

CYTM

GDTC

CYTOMED THERAPEUTICS LTD

(GDTC)

2025 6-K

Summary

Summary

Share Purchase Announcement

22 Oct '25

Cash Bid Announcement

14 Oct '25

Research Collaboration

2 Oct '25

Financial Results Report

30 Sep '25

Company Expansion

28 Aug '25

ATM Offering Program

18 Aug '25

Clinical Trial Update

21 Jul '25

Share Issuance Approval

3 Jul '25

Annual Meeting Results

3 Jul '25

Annual Meeting Notice

16 May '25

Financial Results Update

28 Apr '25

Collaboration Agreement

6 Jan '25

Leadership Changes

5 Dec '24

First Patient Dosed

20 Nov '24

Clinical Trial Funding

7 Oct '24

Asset Acquisition

3 Oct '24

Financial Report Update

30 Sep '24

Board Restructure

24 Jun '24

Board Resignation

20 Jun '24

Annual Shareholders Meeting

24 May '24

Proxy Statement Update

25 Apr '24

Annual Meeting Notice

24 Apr '24

Shareholder Cell Banking

18 Mar '24

Research Partnership

4 Mar '24

Patent Granted

29 Jan '24

External Links:

SEC

CytoMed Therapeutics Ltd filed a Form 6-K reporting its unaudited financial statements and management analysis for the six months ending June 30, 2025, and will hold a conference call on October 2, 2025 to discuss these results.

AI Assistant

CYTOMED THERAPEUTICS LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.